Valeant Pharmaceuticals International Inc

Valeant Pharmaceuticals International — Lazard Capital Markets Annual Life Sciences Conference 2005

10 slides from Valeant Pharmaceuticals International's conference presentation, Nov 30, 2005

  1. Slide 1: Additional Disclosures to Support Presentations at Lazard Conference

    Slide 1: Additional Disclosures to Support Presentations at Lazard Conference

    EXHIBIT 99.2 November 30, 2005 Additional Disclosures to Support Presentations at Lazard Capital Markets Annual Life Sciences Conference During a presentation at the Lazard Capital Markets Annual Life Sciences Conference on November 30, 2005, Valeant Pharmaceuticals International (the “Company”) pre

  2. Slide 2

    Slide 2

  3. Slide 3: Table 2: Adjusted Operating Income Reconciliation, 2003

    Slide 3: Table 2: Adjusted Operating Income Reconciliation, 2003

    Table 2 Valeant Pharmaceuticals International Reconciliation of Adjusted Operating Income and Financial Metrics Excluding Non-GAAP Adjustments to Operating Income and Financial Metrics, as measured under GAAP For the Year Ended December 31, 2003 (In millions) Non-GAAP GAAP Adjustments Adjusted Produ

  4. Slide 4: Table 3: Adjusted Operating Income Reconciliation, 2002

    Slide 4: Table 3: Adjusted Operating Income Reconciliation, 2002

    Table 3 Valeant Pharmaceuticals International Reconciliation of Adjusted Operating Income and Financial Metrics Excluding Non-GAAP Adjustments to Operating Income and Financial Metrics, as measured under GAAP For the Year Ended December 31, 2002 (In millions) Non-GAAP GAAP Adjustments Adjusted Produ

  5. Slide 5: Table 4: Specialty Pharmaceuticals Adjusted Operating Income, 2004

    Slide 5: Table 4: Specialty Pharmaceuticals Adjusted Operating Income, 2004

    Table 4 Valeant Pharmaceuticals International Reconciliation of Specialty Pharmaceuticals Adjusted Operating Income Excluding Non-GAAP Adjustments to Operating Income, as measured under GAAP For the Year Ended December 31, 2004 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty Pharmaceutica

  6. Slide 6: Table 5: Specialty Pharmaceuticals Adjusted Operating Income, 2003

    Slide 6: Table 5: Specialty Pharmaceuticals Adjusted Operating Income, 2003

    Table 5 Valeant Pharmaceuticals International Reconciliation of Specialty Pharmaceuticals Adjusted Operating Income Excluding Non-GAAP Adjustments to Operating Income, as measured under GAAP For the Year Ended December 31, 2003 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty Pharmaceutica

  7. Slide 7: Table 6: Specialty Pharmaceuticals Adjusted Operating Income, 2002

    Slide 7: Table 6: Specialty Pharmaceuticals Adjusted Operating Income, 2002

    Table 6 Valeant Pharmaceuticals International Reconciliation of Specialty Pharmaceuticals Adjusted Operating Income Excluding Non-GAAP Adjustments to Operating Income, as measured under GAAP For the Year Ended December 31, 2002 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty Pharmaceutica

  8. Slide 8: Table 7: EBITDA Reconciliation, 2004

    Slide 8: Table 7: EBITDA Reconciliation, 2004

    Table 7 Valeant Pharmaceuticals International Reconciliation of EBITDA Excluding Non-GAAP Adjustments to EBITDA, as measured under GAAP For the Year Ended December 31, 2004 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty pharmaceuticals Adjusted operating income (from Table 4) $ 50 $ 29(a

  9. Slide 9: Table 8: EBITDA Reconciliation, 2003

    Slide 9: Table 8: EBITDA Reconciliation, 2003

    Table 8 Valeant Pharmaceuticals International Reconciliation of EBITDA Excluding Non-GAAP Adjustments to EBITDA, as measured under GAAP For the Year Ended December 31, 2003 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty pharmaceuticals Adjusted operating income (from Table 5) $ 43 $ — $

  10. Slide 10: Table 9: EBITDA Reconciliation, 2002

    Slide 10: Table 9: EBITDA Reconciliation, 2002

    Table 9 Valeant Pharmaceuticals International Reconciliation of EBITDA Excluding Non-GAAP Adjustments to EBITDA, as measured under GAAP For the Year Ended December 31, 2002 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty pharmaceuticals Adjusted operating income (loss) (from Table 6) $ (2

Source: SEC EDGAR · 8-K filed Nov 30, 2005

More decks from Valeant Pharmaceuticals International Inc